We use cookie
When you visit hemacore.com, you agree that we process your personal data using metric programs.
I understand, thanks
Information materials posted on the website www.hemacore.com, including advertising, graphic images of medical devices are presented exclusively for medical professionals and / or employees of medical or medical research organizations, as well as suppliers of medical devices.

By clicking "Continue" and staying at www.hemacore.com, you acknowledge that you are a medical professional and / or employee of a medical or medical research organization, or a supplier of medical devices and accept responsibility for non-compliance with this limitation.
Continue

Main
About HemaCore
Mission & History

MISSION AND HISTORY

«A pulmonary embolus may be viewed as act of God, impossible to reliable predict or to completely avoid»* — taking up this challenge the company set to develop and manufacture innovative diagnostic systems, translating long-standing research findings of clotting mechanisms into practice.

MISSION AND HISTORY

HemaCore's activities focus on production and introduction into the world clinical practice of fundamentally new and more efficient diagnostic tests to facilitate the assessment of thrombosis risk and adequacy of thromboprophylaxis or therapy and so to bring life-threatening complications such as thrombosis and bleeding under control..

R&D is carried out by HemaCore's subsidiary — HemaCor Labs.

The company's portfolio includes developments of different stages: Thrombodynamics® Assay, Thrombodynamics-4D Assay, fibrinolysis evaluation test, contraction evaluation test, that is laboratory equipment, consumables and special algorithms and software for automatic analysis and calculation of the results obtained.

The company's intellectual property strategy is based on a strong portfolio of patents in various fields (biotechnology, mathematics) covering the most important world markets: the USA, Europe, Eurasia, China, Japan, Canada, Russia – more than 50 objects.

Since the end of 2012 the company worked its way up from commercialization and sales of Thrombodynamics Analyser Systems (IVD devices and kits) in Russian research centers to the inclusion of the Thrombodynamics® assay into national clinical guidelines.

Since 2016 the complete list of the company's products with the RUO status has been exported to the European market, and since 2019, to the North American market.

1994
1994
1997
2002
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2018
2019
2020
2021
2021
12
June
1994
First publication on the autowave nature of coagulation
09
June
1997
The first experimental device is assembled
30
May
2002
First clinical articles were published
09
November
2007
Patent pending
17
March
2008
The first prototype of a clinical device is assembled
30
September
2009
MedIn company established
07
April
2010
HemaCore company was founded
08
December
2011
Device and diagnostic kit for Thrombodynamics Assay
30
November
2012
In Vitro Diagnostic Device labeling in Russia
05
June
2013
Analyser design wins Red Dot Design Awards
30
September
2013
First Guideline with Thrombodynamics
19
November
2014
Round B investment
15
August
1015
Sales started in Europe (research use only)
02
December
2016
Thrombodynamics 4D assay developped
01
June
2018
Winner of Skolkovo Startup Village technology contest
13
February
2019
Sales started in US (research use only)
23
April
2020
We got involved in the fight against COVID-19
11
May
2020
Thrombodynamics Based Fibrinolysis Assessment Now Available to All Research Centers
15
December
2021
In Vitro Diagnostic Device labeling in Kyrgyzstan
29
December
2021
HemaCore has received its EN ISO 13485:2016 Certificate!
1994
1997
2002
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2018
2019
2020
2021
1994
12
June
1994
First publication on the autowave nature of coagulation
The first theoretical work on the spatial aspect of folding has been published.
1997
09
June
1997
The first experimental device is assembled
To test the theoretical hypothesis, the first experimental setup was constructed.
2002
30
May
2002
First clinical articles were published
The discovery of the autowave model led to the formation of new ideas about how the coagulation process proceeds. It turned out that different blocks of reactions are responsible for different phases of the clot formation process (activation, spreading, stopping). This led to a revision of a number of generally accepted ideas. It was believed that the internal coagulation pathway is a "metabolic atavism" and does not play a significant role in coagulation in the body. We have shown that a significant part of the reactions of this metabolic pathway completely determines the nature of the second phase of coagulation - the phase of clot propagation. The journals Hematology and Transfusiology and Biochim Biophys Acta published the first articles on the clinical application of the method.
2007
09
November
2007
Patent pending
A patent application has been filed for "Plasma coagulation research apparatus".
2008
17
March
2008
The first prototype of a clinical device is assembled
Time does not stand still. The scientific team is constantly being updated and new people, and their interest moves forward the research work. In 2008, a new prototype of the device was developed and assembled, which made it possible to increase the number and quality of experiments carried out.
2009
30
September
2009
MedIn company established
To structure the project, the team of authors established the Medical Innovations company, which is the holder of the intellectual property of the project.
2010
07
April
2010
HemaCore company was founded

Hemacore founded. $8.7M Round A investment

2011
08
December
2011
Device and diagnostic kit for Thrombodynamics Assay

Hemacore finished development of the device and diagnostic kit

2012
30
November
2012
In Vitro Diagnostic Device labeling in Russia

Permission from Roszdravnadzor for the use in clinics of Russian Federation

2013
05
June
2013
Analyser design wins Red Dot Design Awards
30
September
2013
First Guideline with Thrombodynamics
The All-Russian Public Organization "Federation of Anesthesiologists and Resuscitators" has approved clinical guidelines for the perioperative management of patients receiving long-term antithrombotic therapy, which includes the Thrombodynamics test!
2014
19
November
2014
Round B investment

$2,4M Round B investment

2015
15
August
1015
Sales started in Europe (research use only)
2016
02
December
2016
Thrombodynamics 4D assay developped
HemaCore finished the development of new Thrombodynamics 4D assay!
2018
01
June
2018
Winner of Skolkovo Startup Village technology contest
HemaCor Labs won the competition of companies at StartupVillage 2018 for the development of the Thrombodynamics test!
More details
2019
13
February
2019
Sales started in US (research use only)
We have begun shipping all commercially available products to the North American market. Our partner is Diapharma.
More details
2020
23
April
2020
We got involved in the fight against COVID-19
Research: Establishing the correlation of a blood clotting disorder detected using the Thrombodynamics test with a negative prognosis for the course of COVID-19 and developing measures to prevent an unfavorable scenario of the course of the disease
More details
11
May
2020
Thrombodynamics Based Fibrinolysis Assessment Now Available to All Research Centers
Now any research center can take advantage of the opportunity to assess the functional state of the fibrinolysis system using our TDL kit, which expands the capabilities of the thrombodynamics test system. The implementation of the project "Commercialization of a diagnostic test for assessing the state of the blood fibrinolysis system on the basis of the Trombodynamics platform is being carried out with the grant support of the Innovation Promotion Foundation www.fasie.ru
2021
15
December
2021
In Vitro Diagnostic Device labeling in Kyrgyzstan
29
December
2021
HemaCore has received its EN ISO 13485:2016 Certificate!
We are proud to announce that HemaCore  has received the ISO 13485:2016 Certificate!
More details

HEMACORE'S MISSION

We transform the results of fundamental research in
highly-demanded medical diagnostics tools.
HEMACORE'S MISSION
Ru
THROMBODYNAMICS
Application
ABOUT HemaCore
Contacts
THROMBODYNAMICS
Thrombodynamics method
Thrombodynamics analyser system
Kits
Parameters & interpretation
Thrombodynamics in the world
Application
Application
Publications
News
For Users
FAQ
ABOUT HemaCore
Mission & History
Distributors
Official documents
THROMBODYNAMICS
Thrombodynamics method Thrombodynamics analyser system Kits Parameters & interpretation Thrombodynamics in the world
Application
Application Publications News For Users FAQ
ABOUT HemaCore
Mission & History Distributors Official documents
Contacts